Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.

Kahraman K, Berker B, Atabekoglu CS, Sonmezer M, Cetinkaya E, Aytac R, Satiroglu H

Fertility and sterility13 Jun 2008Cited by 54 (Europe PMC)

PMID18555238DOI10.1016/j.fertnstert.2008.03.057PepBankPUB-18555238

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In poor responders undergoing ICSI, cetrorelix produced significantly lower estradiol than microdose leuprolide: 1,362 versus 1,904 pg/mL.
In plain wordsIn poor responders undergoing ICSI, estradiol was lower with cetrorelix than microdose leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol on hCG day
Study
n = 42
Comparator
Microdose leuprolide acetate 50 microg twice daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily when the leading follicle reached 14 mmAs given in this study (human).
Measurements
Mean serum estradiol on hCG day
1362 pg/mL
cetrorelix
Mean serum estradiol on hCG day
1904 pg/mL
microdose leuprolide acetate
Source sentences
Summary
The mean serum E(2) concentration on the day of hCG administration was significantly higher in the microdose GnRH-a group than in the GnRH antagonist group (1,904 vs. 1,362 pg/mL).
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, clinical study.
Summary · context
Forty-two poor responder patients undergoing intracytoplasmic sperm injection (ICSI)-embryo transfer cycle.
Summary · context
Twenty-one patients received microdose leuprolide acetate (LA) (50 microg twice daily) starting on the second day of withdrawal bleeding.
Summary · context
The other 21 patients received 0.25 mg of cetrorelix daily when the leading follicle reached 14 mm in diameter.
Report a problemFND-1855523801
02HumanRandomized controlled trialEfficacy outcome
In poor responders undergoing ICSI, clinical pregnancy per started cycle was 9.5% with cetrorelix versus 14.2% with microdose leuprolide.
In plain wordsIn poor responders undergoing ICSI, pregnancy per started cycle was 9.5% with cetrorelix versus 14.2% with microdose leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseClinical pregnancy per started cycle
Study
n = 42
Comparator
Microdose leuprolide acetate 50 microg twice daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily when the leading follicle reached 14 mmAs given in this study (human).
Measurements
Clinical pregnancy rate per started cycle
9.5%
cetrorelix
Clinical pregnancy rate per started cycle
14.2%
microdose leuprolide acetate
Source sentences
Summary
The clinical PRs per started cycle of microdose GnRH-a and GnRH antagonist groups were 14.2% and 9.5%, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, clinical study.
Summary · context
Forty-two poor responder patients undergoing intracytoplasmic sperm injection (ICSI)-embryo transfer cycle.
Summary · context
Twenty-one patients received microdose leuprolide acetate (LA) (50 microg twice daily) starting on the second day of withdrawal bleeding.
Summary · context
The other 21 patients received 0.25 mg of cetrorelix daily when the leading follicle reached 14 mm in diameter.
Report a problemFND-1855523802
03HumanRandomized controlled trialEfficacy outcome
In poor responders undergoing ICSI, other ovulation induction characteristics did not differ significantly between cetrorelix and microdose leuprolide.
In plain wordsIn poor responders undergoing ICSI, other stimulation characteristics did not differ significantly between cetrorelix and microdose leuprolide.
Peptide
Cetrorelix
Outcome
No significant changeOther ovulation induction characteristics
Study
n = 42
Comparator
Microdose leuprolide acetate 50 microg twice daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily when the leading follicle reached 14 mmAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences in the other ovulation induction characteristics, fertilization and implantation rates.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, clinical study.
Summary · context
Forty-two poor responder patients undergoing intracytoplasmic sperm injection (ICSI)-embryo transfer cycle.
Summary · context
Twenty-one patients received microdose leuprolide acetate (LA) (50 microg twice daily) starting on the second day of withdrawal bleeding.
Summary · context
The other 21 patients received 0.25 mg of cetrorelix daily when the leading follicle reached 14 mm in diameter.
Report a problemFND-1855523803
04HumanRandomized controlled trialEfficacy outcome
In poor responders undergoing ICSI, fertilization rates did not differ significantly between cetrorelix and microdose leuprolide.
In plain wordsIn poor responders undergoing ICSI, fertilization rates did not differ significantly between cetrorelix and microdose leuprolide.
Peptide
Cetrorelix
Outcome
No significant changeFertilization rate
Study
n = 42
Comparator
Microdose leuprolide acetate 50 microg twice daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily when the leading follicle reached 14 mmAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences in the other ovulation induction characteristics, fertilization and implantation rates.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, clinical study.
Summary · context
Forty-two poor responder patients undergoing intracytoplasmic sperm injection (ICSI)-embryo transfer cycle.
Summary · context
Twenty-one patients received microdose leuprolide acetate (LA) (50 microg twice daily) starting on the second day of withdrawal bleeding.
Summary · context
The other 21 patients received 0.25 mg of cetrorelix daily when the leading follicle reached 14 mm in diameter.
Report a problemFND-1855523804
05HumanRandomized controlled trialEfficacy outcome
In poor responders undergoing ICSI, implantation rates did not differ significantly between cetrorelix and microdose leuprolide.
In plain wordsIn poor responders undergoing ICSI, implantation rates did not differ significantly between cetrorelix and microdose leuprolide.
Peptide
Cetrorelix
Outcome
No significant changeImplantation rate
Study
n = 42
Comparator
Microdose leuprolide acetate 50 microg twice daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily when the leading follicle reached 14 mmAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences in the other ovulation induction characteristics, fertilization and implantation rates.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, clinical study.
Summary · context
Forty-two poor responder patients undergoing intracytoplasmic sperm injection (ICSI)-embryo transfer cycle.
Summary · context
Twenty-one patients received microdose leuprolide acetate (LA) (50 microg twice daily) starting on the second day of withdrawal bleeding.
Summary · context
The other 21 patients received 0.25 mg of cetrorelix daily when the leading follicle reached 14 mm in diameter.
Report a problemFND-1855523805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.